← feed

Is NCT03146416 results overdue?

Yes — results are overdue. Primary completion was 2018-06-14; the FDAAA-801 reporting deadline (2019-06-14) passed 2610 days ago and no results are posted on ClinicalTrials.gov.

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT IDNCT03146416 ↗
SponsorRegeneron Pharmaceuticals (INDUSTRY)
Public issuerREGENERON PHARMACEUTICALS, INC. — REGN (CIK 0000872589) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-06-14 (ACTUAL)
Reporting deadline2019-06-14 (completion + 365d)
Days overdue2610
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 711eb03b7c3375af… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03146416. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →